Brodalumab
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, vol.56, pp.58-60, 2022 (ESCI, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 56
- Publication Date: 2022
- Doi Number: 10.4274/turkderm.galenos.2022.01643
- Journal Name: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Page Numbers: pp.58-60
- Keywords: Anti-IL-17RA, brodalumab, psoriasis
- Open Archive Collection: AVESIS Open Access Collection
- Erciyes University Affiliated: Yes
Abstract
Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75 response has been achieved in 82-84% of the patients at week 12. It was shown to be effective also in generalized pustular and erythrodermic psoriasis. As with other IL-17 inhibitors, brodalumab should be used with caution in patients with inflammatory bowel disease.